SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: tuck who wrote (561)9/16/2001 7:08:04 PM
From: tnsaf  Read Replies (2) | Respond to of 3557
 
A fixed format version of the table makes it easier to see
what is going on. From this study, 1.0 mcg/kg is better
than 2.0 mcg/kg, which will help allay safety concerns.

Mean Change from Baseline Weight (Pounds)
All Available Data for All Patients

AXOKINE
Placebo 0.3 mcg/kg 1.0 mcg/kg 2.0 mcg/kg Combined
AXOKINE

12 Weeks + 0.2 -3.5 -9.1 -8.0 -6.9
(end of
blinded
treatment) (n=23) (n=23) (n=26) (n=19) (n=68)
18 Weeks + 2.2 -4.7 -9.6 -7.8 -7.4
(6 weeks off
treatment) (n=19) (n=22) (n=25) (n=18) (n=65)
24 weeks + 1.9 -4.8 -9.9 -5.8 -7.1
(12 weeks off
treatment) (n=19) (n=18) (n=23) (n=17) (n=58)
36 weeks + 3.8 -4.4 -12.4 -5.4 -7.8
(24 weeks off
treatment) (n=16) (n=18) (n=19) (n=12) (n=49)
48 weeks + 3.1 -2.9 -12.4 -3.9 -6.7
(36 weeks off
treatment) (n=16) (n=17) (n=17) (n=11) (n=45)

Results for just those patients who completed the full 48 weeks in
the study are:

Mean Change from Baseline Weight (Pounds)
Data for Patients Who Completed 48 Weeks of Follow-up

AXOKINE Combined
Placebo 0.3 mcg/kg 1.0 mcg/kg 2.0 mcg/kg AXOKINE
n=16 n=17 n=17 n=11 n=45

12 Weeks + 1.1 -5.0 -10.4 -8.0 -7.8
(end of
blinded
treatment)
18 Weeks + 3.5 -5.4 -12.0 -9.7 -8.8
(6 weeks off
treatment)
24 weeks + 2.7 -5.0 -13.1 -7.7 -8.8
(12 weeks off
treatment)
36 weeks +3.8 -4.7 -15.6 -5.4 -8.8
(24 weeks off
treatment)
48 weeks +3.1 -2.9 -12.4 -3.9 -6.7
(36 weeks off
treatment)